— Know what they know.
Not Investment Advice
Also trades as: 0A8E.L (LSE) · $vol 0M

XERS NASDAQ

Xeris Biopharma Holdings, Inc.
1W: -6.8% 1M: +12.2% 3M: +23.9% YTD: +38.9% 1Y: +11.8% 3Y: +490.2% 5Y: +446.0%
$10.45
+0.24 (+2.35%)
After Hours: $10.38 (-0.07, -0.67%)
Weekly Expected Move ±9.7%
$8 $9 $10 $11 $12
NASDAQ · Healthcare · Biotechnology · Tech Score Buy · Power 69 · $1.9B mcap · 173M float · 1.32% daily turnover · Short 33% of daily vol
Credit Risk of going bust: higher than 53% of companies Debt: 13.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.19 (down 98%), Xeris Biopharma Holdings, Inc. would be worth roughly what it owes.
Total debt $289.4M against a stock market value of $1.86B.
Distance to default 4.87 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $158.2M (short-term plus half of long-term), stock volatility 54.6%; Altman Z'' -4.14. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Balance Sheet Trends

Total Assets
$384M +18.7% ▲
5Y CAGR: +19.2%
Total Liabilities
$370M +4.9% ▲
5Y CAGR: +24.2%
Shareholders Equity
$14M +146.2% ▲
5Y CAGR: -16.5%
Cash & Investments
$111M +55.0% ▲
5Y CAGR: -3.7%
Total Debt
$38M -86.1% ▼
5Y CAGR: -15.4%
Net Debt
-$73M -136.7% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$67M$122M$67M$72M$111M
Short-Term Investments$35M$0$5M$0$0
Cash & ST Investments$102M$122M$72M$72M$111M
Net Receivables$17M$31M$39M$40M$51M
Inventory$18M$25M$39M$48M$69M
Other Current Assets$0$9M$6M$7M$10M
Total Current Assets$143M$187M$156M$168M$240M
Property, Plant & Equip.$7M$10M$29M$28M$27M
Goodwill & Intangibles$154M$143M$133M$122M$111M
Long-Term Investments$0$0$0$4M$0
Other Non-Current Assets$829K$5M$5M-$5M$5M
Total Non-Current Assets$162M$158M$166M$155M$143M
Total Assets$304M$345M$323M$323M$384M
— Liabilities —
Accounts Payable$9M$5M$12M$2M$3M
Short-Term Debt$0$0$0$15M$6M
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$26M$27M$51M$40M$100M
Total Current Liabilities$79M$74M$95M$100M$110M
Long-Term Debt$88M$187M$191M$217M$32M
Other Non-Current Liab.$37M$26M$6M$2M$229M
Total Non-Current Liabilities$130M$226M$234M$252M$260M
Total Liabilities$209M$299M$329M$353M$370M
— Equity —
Common Stock$13K$14K$14K$15K$17K
Retained Earnings-$460M-$555M-$617M-$672M-$671M
Accumulated OCI-$31K-$23K-$25K-$25K-$25K
Total Stockholders Equity$95M$45M-$7M-$30M$14M
Total Liabilities & Equity$304M$345M$323M$323M$384M
— Key Metrics —
Total Debt$88M$198M$229M$271M$38M
Net Debt$21M$76M$162M$200M-$73M
Total Investments$35M$0$5M$4M$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms